JP2020506962A5 - - Google Patents

Download PDF

Info

Publication number
JP2020506962A5
JP2020506962A5 JP2019560066A JP2019560066A JP2020506962A5 JP 2020506962 A5 JP2020506962 A5 JP 2020506962A5 JP 2019560066 A JP2019560066 A JP 2019560066A JP 2019560066 A JP2019560066 A JP 2019560066A JP 2020506962 A5 JP2020506962 A5 JP 2020506962A5
Authority
JP
Japan
Prior art keywords
seq
hla
antibody
neoantigen
cancer cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019560066A
Other languages
English (en)
Japanese (ja)
Other versions
JP7303750B2 (ja
JP2020506962A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/015086 external-priority patent/WO2018140525A1/en
Publication of JP2020506962A publication Critical patent/JP2020506962A/ja
Publication of JP2020506962A5 publication Critical patent/JP2020506962A5/ja
Priority to JP2023102868A priority Critical patent/JP2023134503A/ja
Application granted granted Critical
Publication of JP7303750B2 publication Critical patent/JP7303750B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019560066A 2017-01-24 2018-01-24 癌における非古典的ｈｌａ－ｉおよびネオ抗原を含む複合体を標的とするための方法および組成物 Active JP7303750B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023102868A JP2023134503A (ja) 2017-01-24 2023-06-22 癌における非古典的ｈｌａ－ｉおよびネオ抗原を含む複合体を標的とするための方法および組成物

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762449954P 2017-01-24 2017-01-24
US62/449,954 2017-01-24
US201762460585P 2017-02-17 2017-02-17
US62/460,585 2017-02-17
PCT/US2018/015086 WO2018140525A1 (en) 2017-01-24 2018-01-24 Methods and compositions for targeting a complex comprising non-classical hla-i and neoantigen in cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023102868A Division JP2023134503A (ja) 2017-01-24 2023-06-22 癌における非古典的ｈｌａ－ｉおよびネオ抗原を含む複合体を標的とするための方法および組成物

Publications (3)

Publication Number Publication Date
JP2020506962A JP2020506962A (ja) 2020-03-05
JP2020506962A5 true JP2020506962A5 (https=) 2021-03-04
JP7303750B2 JP7303750B2 (ja) 2023-07-05

Family

ID=62979691

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019560066A Active JP7303750B2 (ja) 2017-01-24 2018-01-24 癌における非古典的ｈｌａ－ｉおよびネオ抗原を含む複合体を標的とするための方法および組成物
JP2023102868A Pending JP2023134503A (ja) 2017-01-24 2023-06-22 癌における非古典的ｈｌａ－ｉおよびネオ抗原を含む複合体を標的とするための方法および組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023102868A Pending JP2023134503A (ja) 2017-01-24 2023-06-22 癌における非古典的ｈｌａ－ｉおよびネオ抗原を含む複合体を標的とするための方法および組成物

Country Status (5)

Country Link
US (1) US20190071502A1 (https=)
EP (1) EP3573997A4 (https=)
JP (2) JP7303750B2 (https=)
CN (1) CN110809580A (https=)
WO (1) WO2018140525A1 (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA49156A (fr) 2014-12-23 2020-03-25 Immatics Biotechnologies Gmbh Nouveaux peptides et combinaison de peptides à utiliser dans l'immunothérapie contre le carcinome hépatocellulaire (hcc) et d'autres cancers
GB201501017D0 (en) 2014-12-23 2015-03-04 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers
EP3539552A1 (en) * 2018-03-16 2019-09-18 Deutsches Rheuma-Forschungszentrum Berlin Activation and expansion of nkg2c+ nk cells
US20210253713A1 (en) * 2018-07-23 2021-08-19 Abexxa Biologics, Inc. Antibodies targeting a complex comprising non-classical hla-i and neoantigen and their methods of use
CN113366312A (zh) * 2018-11-01 2021-09-07 伯克利之光生命科技公司 在微流体环境中测定生物细胞的方法
KR20220031668A (ko) * 2019-07-05 2022-03-11 인텔렉슨 게엠베하 의학 및 진단에서의 hla-h
CN110491450B (zh) * 2019-08-23 2023-05-16 深圳市新合生物医疗科技有限公司 肿瘤新生抗原预测平台及其应用
JP2022553073A (ja) * 2019-10-25 2022-12-21 インテレクソン ゲゼルシャフト ミット ベシュレンクテル ハフツング 治療・診断標的としてのｈｌａ－ｈ， ｈｌａ－ｊおよびｈｌａ－ｌ
CA3183756A1 (en) 2020-05-19 2021-11-25 Amgen Inc. Mageb2 binding constructs
US10981996B1 (en) * 2020-06-01 2021-04-20 Abexxa Biologics, Inc. Antibodies targeting a complex comprising non-classical HLA-I and neoantigen and their methods of use
US11976120B2 (en) * 2020-06-01 2024-05-07 Boehringer Ingelheim International Gmbh Antibodies targeting a complex comprising non-classical HLA-I and neoantigen and their methods of use
US10981997B1 (en) * 2020-06-01 2021-04-20 Abexxa Biologics, Inc. Antibodies targeting a complex comprising non-classical HLA-I and neoantigen and their methods of use
US20230303698A1 (en) * 2020-06-30 2023-09-28 Harbour Biomed (Shanghai) Co., Ltd Multispecific binding protein of immune cell engager, preparation therefor and application thereof
CN115667316A (zh) * 2020-06-30 2023-01-31 和铂医药(上海)有限责任公司 Fab-HCAb结构的结合蛋白
JP7620780B2 (ja) * 2020-06-30 2025-01-24 ノナ・バイオサイエンシーズ・（シャンハイ）・カンパニー・リミテッド Ｈ２Ｌ２とＨＣＡｂ構造を有する結合タンパク質
US20250051454A1 (en) * 2020-09-15 2025-02-13 Duke University Antibodies that target hla-e-host peptide complexes and uses thereof
EP4388012A4 (en) * 2021-08-20 2025-09-17 Univ Duke ANTIBODIES TARGETING HLA-E-HOST PEPTIDE COMPLEXES AND THEIR USES
WO2023112965A1 (ja) * 2021-12-15 2023-06-22 学校法人帝京平成大学 Ｖｈｈ抗体
EP4598569A1 (en) * 2022-10-05 2025-08-13 Tscan Therapeutics, Inc. Magea1 immunogenic peptides, binding proteins recognizing magea1 immunogenic peptides, and uses thereof
WO2024084091A1 (en) * 2022-10-21 2024-04-25 Medizinische Universität Wien Materials and methods to treat epstein-barr virus (ebv) and ebv-induced diseases
WO2025064029A1 (en) * 2023-09-22 2025-03-27 Regeneron Pharmaceuticals, Inc. Methods for obtaining antibody molecules binding to a peptide-mhc interface
GB202316281D0 (en) * 2023-10-24 2023-12-06 Replay Holdings Inc Methods and compositions for modulating immune cell activity in cellular therapy
WO2026024596A1 (en) * 2024-07-22 2026-01-29 The Children's Hospital Of Philadelphia Methods of stimulating an immune response

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI9809391B8 (pt) * 1997-04-14 2021-05-25 Amgen Res Munich Gmbh processo para a produção de um receptor de antígeno anti-humano, anticorpo humano e composição farmacêutica
ATE533784T1 (de) * 1997-10-02 2011-12-15 Altor Bioscience Corp Lösliche, einzelkettige proteine des t- zellrezeptors
GB9725764D0 (en) 1997-12-04 1998-02-04 Isis Innovation HLA-E binding
DK1276896T3 (da) * 2000-04-28 2010-10-18 Mannkind Corp Epitop-synkronisering i antigen-præsenterende celler
EP2769731A1 (en) 2007-02-23 2014-08-27 The Trustees of Columbia University in the City of New York Methods to activate or block the HLA-E/QA-1 restricted CD8+ T cell regulatory pathway to treat immunological disease
EP2144935A2 (en) * 2007-03-29 2010-01-20 Technion Research & Development Foundation Ltd. Antibodies, methods and kits for diagnosing and treating melanoma
GB201003198D0 (en) * 2010-02-25 2010-04-14 Arab Biotechnology Company Compositions and methods for the treatment of cancer
JP2013541937A (ja) * 2010-08-05 2013-11-21 エフ．ホフマン−ラ ロシュ アーゲー 抗ｍｈｃ抗体−抗ウイルス性サイトカイン融合タンパク質
US9290541B2 (en) * 2011-11-18 2016-03-22 Board Of Regents, The University Of Texas System TCL1 peptides for immunotherapy
US10656156B2 (en) * 2012-07-05 2020-05-19 Mepur Ravindranath Diagnostic and therapeutic potential of HLA-E monospecific monoclonal IgG antibodies directed against tumor cell surface and soluble HLA-E
DK3078744T3 (da) * 2013-12-04 2020-09-28 Chugai Pharmaceutical Co Ltd Antigen-bindende molekyler, antigen-bindingsaktiviteten af hvilke varierer i henhold til koncentrationen af forbindelser, og biblioteker af molekylerne
GB201505305D0 (en) * 2015-03-27 2015-05-13 Immatics Biotechnologies Gmbh Novel Peptides and combination of peptides for use in immunotherapy against various tumors
NL2014935B1 (en) * 2015-06-08 2017-02-03 Applied Immune Tech Ltd T cell receptor like antibodies having fine specificity.
HK1248255A1 (zh) * 2015-06-24 2018-10-12 优瑞科生物技术公司 靶向ny-eso-1肽/mhc复合物的构建体及其用途
EP3475706B1 (en) * 2016-06-27 2021-08-11 Juno Therapeutics, Inc. Mhc-e restricted epitopes, binding molecules and related methods and uses

Similar Documents

Publication Publication Date Title
JP2020506962A5 (https=)
ZA202206437B (en) Claudin18.2 binding moieties and uses thereof
JOP20190248A1 (ar) بروتينات ربط مولد ضد trem2 واستخداماته
MY207205A (en) Cd3 antibody and pharmaceutical use thereof
JP2015535691A5 (https=)
PE20191717A1 (es) Dominio de union antigeno anti-trbc1
JP2015535689A5 (https=)
NZ726520A (en) Tri-specific binding molecules that specifically bind to multiple cancer antigens and methods of use thereof
MX375379B (es) Receptores de celulas t anti - papilomavirus 16 e7 humano.
JP2020524506A5 (https=)
JP2018524987A5 (https=)
JP2017535292A5 (https=)
JP2009526823A5 (https=)
CR20200014A (es) Molécula de polipéptido con especificidad dual mejorada
JO3744B1 (ar) مواد ربط لـpd1 و/ أو lag3
WO2016077840A3 (en) Variable new antigen receptors (vnars) directed against transferrin receptor (tfr) and their use
JP2017513478A5 (https=)
JP2019527041A5 (https=)
EP4647446A3 (en) Therapeutic antibodies and their uses
JP2016500251A5 (https=)
MX2020009475A (es) Inmunoterapia con celulas car de anticuerpos biespecificos.
JP2018504143A5 (https=)
JP2020516305A5 (https=)
JP2019525898A5 (https=)
JP2015083010A5 (https=)